Lay Sciences | Shefah Ventures

Innovating for the future of human health

Our approach involves offering wellness solutions at a fraction of the cost compared to major pharmaceutical companies. By doing so, we aspire to democratize access to healthcare, empowering individuals to take control of their health without the burden of exorbitant expenses. Lay Sciences recognizes the disparities in healthcare access and endeavors to bridge the gap, fostering a healthier and more equitable society.

Satish Chandran, Ph.D.

CEO and President, Lay Sciences

Novel Products to Prevent or Treat Intractable Unmet Diseases

=

Proprietary Products

Exclusive WW Licensee of ImmunIgY OTC and other products.

=

Unmet Needs Addressed

Anti-respiratory pathogen(s) products, Oral Health Products and GI Health Products.

=

Strong Product Pipeline

Besides the OTC products in Lay Science’s pipeline, Lay Sciences’ portfolio include regulated products that address major significant unmet needs and markets worldwide.

Proprietary IgY-Based Therapeutics

IgY-based antimicrobial therapy offers a unique opportunity to target specific organisms unlike antibiotics, and offer multiple targets of the organisms with extremely low probability of escape mutants. Lay Sciences’ platform allows for rapid development and market introduction of several novel products each year.

Lower Blood Sugar Safely

Lay Sciences’ diabetes products address the unmet need by improving utilization of glucose by muscle and by
targeting the glucose transporters in the gut and thus prevent uptake of dietary glucose into blood.

Alternative to Antibiotics

Immunotherapy through transfer of pre-made antibodies that neutralize influenza and viruses that cause common
cold. Safe, flavored nutritional supplement that may beconsumed multiple times every day.



Oral dosing of IgY antibodies allows for therapeutic interventions and for prophylaxis in a targeted manner. Therapeutic targets that were previously considered undruggable.



Oral dosing avoids systemic exposure. Thereby, reducing the unpleasant side effects and loss of efficacy.



Proprietary formulations that protect IgY from gastric acids and proteases. Allows for release of antibodies to targeted
regions of the gut.



Antibodies are metabolized similarly as other ingested proteins.

Key Team Members with Over $200 Billion in Tx and Dx Launches and Discoveries

Nearly 75 Years Executive Experience at Pharma & Startups

Satish Chandran, Ph.D.

30+ years of Leadership Experience in Vaccines, Drugs, Biologics & Medical Devices

Uday Saxena, Ph.D.

30+ years of Leadership Experience in Drug Discovery

Chetan M. Bangera

30+ years of Leadership Experience in Pharma Marketing – Innovators, Generics and Biologics

Gopi Kadiyala, Ph.D.

10+ years of experience in Diagnostic and IgY technology

More information

Case study / trial info below

Clinical trial info coming soon

Any Questions?

We’ll answer your questions and get back to you within 24 hours.

Your Name *

Your Email Address *

Your Company

I declare that, and can show proof of an annual income exceeding $200,000 ($300,000 for joint income) for the last two years with the expectation of earning the same or a higher income in the current year. Or, have a net income of more that $1 million. Or, have a series 7, 65, or 82 license. I declare that, and can show proof of an annual income exceeding $200,000 ($300,000 for joint income) for the last two years with the expectation of earning the same or a higher income in the current year. Or, have a net income of more that $1 million. Or, have a series 7, 65, or 82 license. I confirm the above declaration

We’ll contact you within 24 hours of your submission.